{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-090667","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.081283+00:00","generated_at":"2026-06-26T12:20:52.881993+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AlloVir appoints Shawn Tomasello to board; co-founder John Wilson to retire","bullets":["Shawn Tomasello appointed to Board of Directors effective March 29, 2022, serving as Class III director until 2023 annual meeting.","John Wilson, co-founder and former executive director, will retire and not stand for re-election at 2022 annual meeting.","Ms. Tomasello brings over 35 years of life sciences experience, with specific expertise in cell and gene therapy commercialization.","Board determined Ms. Tomasello is independent under Nasdaq listing standards; she will receive standard non-employee director compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-090667","json":"https://secwatch.observer/filing/0001193125-22-090667.json","markdown":"https://secwatch.observer/filing/0001193125-22-090667.md","text":"https://secwatch.observer/filing/0001193125-22-090667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522090667/0001193125-22-090667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522090667/d295737d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T12:20:52.881993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49e95a2ccf","claim":"Shawn Tomasello was appointed as director at Kalaris Therapeutics, Inc..","evidence_excerpt":"On March 29, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of AlloVir, Inc. (“AlloVir”), the Board appointed Shawn Tomasello to the Board, effectively immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522090667/0001193125-22-090667-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"}],"fact_type":"executive_change"},{"claim_id":"b66d6a83d7","claim":"John Wilson departed as director at Kalaris Therapeutics, Inc..","evidence_excerpt":"on March 29, 2022, John Wilson notified the Board that he will be retiring from the Board and will not stand for re-election at AlloVir’s 2022 annual meeting of shareholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522090667/0001193125-22-090667-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retiring"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}